Miramar Capital LLC Grows Position in Abbott Laboratories (NYSE:ABT)

Miramar Capital LLC boosted its holdings in Abbott Laboratories ( NYSE:ABT – Free Report ) by 1.5% in the second quarter, Holdings Channel.com reports.

The institutional investor owned 112,211 shares of the healthcare product maker’s stock after acquiring an additional 1,695 shares during the period. Abbott Laboratories makes up 2.9% of Miramar Capital LLC’s portfolio, making the stock its 18th largest holding.



Miramar Capital LLC’s holdings in Abbott Laboratories were worth $11,660,000 as of its most recent SEC filing. Other hedge funds and other institutional investors have also bought and sold shares of the company. Hanson & Doremus Investment Management lifted its position in Abbott Laboratories by 0.

8% during the second quarter. Hanson & Doremus Investment Management now owns 11,165 shares of the healthcare product maker’s stock valued at $1,160,000 after purchasing an additional 92 shares during the period. Encompass More Asset Management lifted its holdings in shares of Abbott Laboratories by 3.

3% during the 2nd quarter. Encompass More Asset Management now owns 3,002 shares of the healthcare product maker’s stock valued at $312,000 after buying an additional 96 shares during the period. Wynn Capital LLC boosted its stake in shares of Abbott Laboratories by 2.

9% in the 1st quarter. Wynn Capital LLC now owns 3,427 shares of the healthcare product maker’s stock worth $390,000 after buying an additional 98 shares during the last quarter. NORTHSTAR ASSET MANAGEMENT Co LLC grew its holdings in shares of Abbott Laboratories by 1.

9% in the first quarter. NORTHSTAR ASSET MANAGEMENT Co LLC now owns 5,396 shares of the healthcare product maker’s stock worth $613,000 after acquiring an additional 100 shares during the period. Finally, Hummer Financial Advisory Services Inc increased its position in Abbott Laboratories by 1.

2% during the first quarter. Hummer Financial Advisory Services Inc now owns 8,290 shares of the healthcare product maker’s stock valued at $942,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 75.

18% of the company’s stock. Insider Activity at Abbott Laboratories In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the stock in a transaction dated Thursday, September 12th.

The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39.

Following the completion of the transaction, the chief executive officer now owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website .

1.10% of the stock is currently owned by corporate insiders. Wall Street Analyst Weigh In Check Out Our Latest Analysis on ABT Abbott Laboratories Price Performance Shares of Abbott Laboratories stock opened at $114.

87 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.

68 and a debt-to-equity ratio of 0.33. Abbott Laboratories has a 52 week low of $89.

67 and a 52 week high of $121.64. The stock’s 50-day simple moving average is $110.

12 and its 200-day simple moving average is $108.61. The company has a market capitalization of $199.

83 billion, a price-to-earnings ratio of 35.79, a PEG ratio of 2.90 and a beta of 0.

72. Abbott Laboratories ( NYSE:ABT – Get Free Report ) last posted its quarterly earnings results on Thursday, July 18th. The healthcare product maker reported $1.

14 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.04.

The business had revenue of $10.38 billion during the quarter, compared to the consensus estimate of $10.37 billion.

Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%.

The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.

08 EPS. As a group, analysts expect that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.

About Abbott Laboratories ( Free Report ) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Articles Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories ( NYSE:ABT – Free Report ). Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.

com's FREE daily email newsletter ..